Clinical Trials Logo

Radiation Injuries clinical trials

View clinical trials related to Radiation Injuries.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04067310 Enrolling by invitation - Radiodermatitis Clinical Trials

Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.

Start date: December 16, 2020
Phase: N/A
Study type: Interventional

This is a randomized, open-label, single-institution trial designed to evaluate the effectiveness of a spray skin protector in preventing moist desquamation caused by radiotherapy treatment. This technology, spray skin protection, depending on the manufacturer, is primarily intended to prevent or reduce contact dermatitis. However, this study will be evaluated for use in preventing moist desquamation caused by ionizing radiation. The comparing agent will be a moisturizer, agreed upon at the local Institution of the study for use in the prevention of radiodermatitis. As secondary objectives: describe adverse events, diarrhea, pain and pruritus. The study will be conducted at the radiotherapy outpatient clinic of the Cancer Hospital I (HCI) of National Cancer Institute (INCA) in Brazil.

NCT ID: NCT02483650 Enrolling by invitation - Clinical trials for Carbon Monoxide Poisoning

Hyperbaric Oxygen Therapy Registry

HBOTR
Start date: January 2005
Phase:
Study type: Observational [Patient Registry]

The purpose of the Hyperbaric Oxygen Therapy Registry (HBOTR) is to provide real world patient outcome and side effect information from electronic health records submitted to a specialty specific hyperbaric registry as part of "Stage 2 of Meaningful Use," including data provided to meet PQRS requirements via the registry's QCDR mission. Goals include understanding the value of HBOT among patients treated for a variety of conditions in relation to the frequency and severity of HBOT side effects. While randomized, controlled trials can establish the efficacy of treatments like HBOT, because they routinely exclude patients with co-morbid conditions common to those patients seen in usual clinical practice, the results of RCTs are usually non-generalizable. Real world data can be used to better understand the effectiveness of HBOT among typical patients, as well as the risks associated with treatment.